Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKAZAR: NVL-655 versus alectinib in treatment-naive ALK-positive advanced NSCLC
NL-OMON60671Phase 3Recruiting
- Sponsor
- Nuvalent
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of neladalkib in non-small cell lung cancer (NSCLC), sponsored by Nuvalent. Started Dec 2025; status: recruiting.
02
Drugs
neladalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60671.